Department of Pharmacology, Universal College of Medical Sciences, Bhairahawa, Rupandehi, Nepal.
Department of Pharmacy, Universal College of Medical Sciences, Bhairahawa, Rupandehi, Nepal.
JNMA J Nepal Med Assoc. 2022 Sep 1;60(253):800-804. doi: 10.31729/jnma.7674.
Dry eye disease is a disorder of the tears and ocular surface that results in various symptoms, such as dryness, grittiness, burning and itching sensation in the eye, excessive tearing, and fluctuating vision. The prevalence of dry eye disease symptoms is increased with long-term topical anti-glaucoma medicine treatment. The objective of this study was to find out the prevalence of dry eye disease in glaucoma patients under topical anti-glaucoma agents in a tertiary care centre.
A descriptive cross-sectional study was conducted from 9 February 2022 to 5 June 2022 among glaucoma patients under topical anti-glaucoma agents at a tertiary care centre after receiving ethical approval from the Institutional Review Committee (Reference number: UCMS/IRC/028/22). Data were collected using a standard ocular surface disease index questionnaire. The dry eye disease was clinically diagnosed if the ocular surface disease index score was equal to or more than 13. Point estimate and 95% Confidence Interval were calculated.
Among 250 glaucoma patients, dry eye disease was found in 180 (72%) (66.43-77.57, 95% Confidence Interval). Mild, moderate, and severe symptoms were present in 50 (27.78%), 68 (37.78%), and 62 (34.44%) of the patients, respectively. The most frequently observed dry eye symptoms were itching and irritation seen in 56 (31.11%), followed by pain in the eye in 41 (22.77%) and redness in the eye in 32 (17.77%) patients.
The prevalence of dry eye disease was higher than other clinical studies done in similar setting. It is extremely concerning and calls for increased focus on managing glaucoma and concurrent dry eye disease.
干眼症是一种泪液和眼表疾病,会导致各种症状,如眼睛干燥、磨砂感、烧灼感、瘙痒感、过度流泪和视力波动。长期使用局部抗青光眼药物会增加干眼症症状的发生率。本研究旨在了解在一家三级保健中心使用局部抗青光眼药物的青光眼患者中干眼症的患病率。
在获得机构审查委员会(参考号:UCMS/IRC/028/22)的伦理批准后,于 2022 年 2 月 9 日至 2022 年 6 月 5 日,对在一家三级保健中心使用局部抗青光眼药物的青光眼患者进行了一项描述性横断面研究。使用标准眼表面疾病指数问卷收集数据。如果眼表面疾病指数评分等于或大于 13,则临床诊断为干眼症。计算了点估计值和 95%置信区间。
在 250 名青光眼患者中,发现 180 名(72%)(95%置信区间为 66.43-77.57)患有干眼症。轻度、中度和重度症状分别见于 50 名(27.78%)、68 名(37.78%)和 62 名(34.44%)患者。最常见的干眼症症状是瘙痒和刺激,见于 56 名(31.11%)患者,其次是眼痛,见于 41 名(22.77%)患者,眼红见于 32 名(17.77%)患者。
干眼症的患病率高于在类似环境中进行的其他临床研究。这是一个非常令人关注的问题,需要更加关注管理青光眼和并发干眼症。